Trial Profile

A phase II study of ABI-007 in combination with Ramucirumab in patients with unresectable/recurrent gastric cancer refractory to prior chemotherapy containing fluoropyrimidines

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Aug 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
Indications Gastric cancer
Focus Therapeutic Use
Sponsors Taiho Pharmaceutical

Most Recent Events

03 Aug 2018 Status changed from active, no longer recruiting to completed.
17 Jan 2018 Primary endpoint (overall response rate (ORR))has been met, according to results published in the European Journal of Cancer.
17 Jan 2018 Results assessing the efficacy and safety of nab-paclitaxel plus ramucirumab combination therapy in patients with AGC refractory to firstline chemotherapy, were published in the European Journal of Cancer.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com